Clinical Adjudication of Hemodialysis Catheter-Related Bloodstream Infections: Findings from the REDUCCTION Trial
Jayson Catiwa,Martin Gallagher,Benjamin Talbot,Peter G Kerr,David J Semple,Matthew A Roberts,Kevan R Polkinghorne,Nicholas A Gray,Girish Talaulikar,Alan Cass,Sradha Kotwal,REDUCCTION Investigators,Omar Tombocon,Rowan Walker,Scott Wilson,Senthil Kumar Balakrishnan,David Fernandes,Hemant Kulkarni,Casey Light,Jo Ryan,Emma Marsh,Jason Wei,David Semple,Vilma Lleva,Lucy Mwangi,Peter Mount,Maree Ross-Smith,Marieke Veenendaal,Vicki Smith,Christine Somerville,Shaun Davidson-West,Natalie Grainer,Stella Green,Murty Mantha,Kati Thiessen,Alison Winsbury,Irene Yao,Emily Neville,Khalilah Marquez,Mona Razavian,Lisa Tienstra,Glenn Stewart,Cathy Chan,Peta McLean,Lawrence McMahon,Matthew Roberts,Monika Chang,Anna Chiam,Duncan Wright,Orla O'Brien,Ramyasuda Swaminathan,Samadhi Wimalasena,Harish Puttagunta,Jeffrey Barbara,Amanda Luke,Margaret Pummeroy,Kim Torpey,Gemma Nicholls,Amy Swinbank,Thomas Titus,Julia Bell,David Johnson,Peter Choi,Ginger Chu,Leanne Garvey,Alastair Gillies,Josephine Chow,Imelda De Guzman,Jeanny Gando,Jeffrey Wong,Richard Nguyen,Roy Cherian,Raye Gillard,Rachel James,Michael Burke,Leanne Glancy,Shimbie Lewis,Richard Baer,Sophie Wade,Daniel Lin,Fortune Ngwenya,Anupkumar Narayanankutty,Kate Fitt,Peter Kerr,Kevan Polkinghorne,Mechelle Seneviratne,Muralikrishna Komala,Junie McCourt,Craig Lawlor,Michaela Kelleher,Amanda Coburn,Sarah Guo,Joanna Sudak,Diana Leary,Jenny Anderson,Thin Han,Tresna Titmarsh,Emily Adam,Bronwyn Hockley,Jenny Latte,Yvonne Matthew,Stephen McDonald,Chen Au Peh,Rebecca Taylor,David McIntyre,Sharadchandra Ratanjee,Karolynn Maurice,Fiona Rettie,Madhivanan Sundaram,Naomi Grimshaw,Matthew Jose,Gail Read,Jayne Amy,Patricia Coutts,Maria Presno,Nigel Toussaint,Debbie Knagge,Colleen Van Senden,Linh Pham,Muh Geot Wong,Jane Nicholson,Paul Snelling,Neil Boudville,Alison Farmer,Ingrid Holmes,Victoria Link,Vivien Perreau,Nicole Warnecke,Sunil Badve,Yanella Martinez-Smith,Frank Ierino,Emmet O'flaherty,Nicholas Gray,Gerald Hilder,Kaylene Wadd,Andrea Pollock,Stanley Searle,Stephen May,Cheryl Wertheim,Jill Telfer,Sarah Coggan,Casey Yates,Kathryn Higgins,Earl James,Alison Coenen,Kris Rogers,Gian Luca Di Tanna,Jayanthi Mysore,Joseph Alvin Santos,Katrina Thistlethwaite,Elizabeth Coroneos,Shannon Nugent,Ian Fox,Sree Venuthurupalli,Helen O'Connell,Deborah Peek,Kannaiyan Rabindranath,Christine Torrie,Tania Smith,Andrew Henderson,Naveed Ahmed,Vinish Thekkoot Vasudevan,Grant Pidgeon,Jennifer Connor,Ruth Thachaw,Sandra Crikis,Lynda Cumming,William Billy Stewart,Sharen Supershad,Pauline Byrne,Karumathil Murali,Hicham Cheikh Hassan,Lin Huang,Romiereeza Dizon,Deepika Joshi,Jon Mendoza,Bishi Augustine,Disha Balraj,Vincent Lee,David O'Donnell,Khin Myint
DOI: https://doi.org/10.34067/KID.0000000000000389
2024-04-01
Kidney360
Abstract:Key Points: The inter-rater reliability of reporting hemodialysis catheter-related infectious events between site investigators and trial adjudicators in Australia and New Zealand was substantial.The high concordance level in reporting catheter infections improves confidence in using site-level bacteremia rates as a clinical metric for quality benchmarking and future pragmatic clinical trials.A rigorous adjudication protocol may not be needed if clearly defined criteria to ascertain catheter-associated bacteremia are used. Background: Hemodialysis catheter-related bloodstream infection (HD-CRBSI) are a significant source of morbidity and mortality among dialysis patients, but benchmarking remains difficult because of varying definitions of HD-CRBSI. This study explored the effect of clinical adjudication process on HD-CRBSI reporting. Methods: The REDUcing the burden of Catheter ComplicaTIOns: a National approach trial implemented an evidence-based intervention bundle using a stepped-wedge design to reduce HD-CRBSI rates in 37 Australian kidney services. Six New Zealand services participated in an observational capacity. Adult patients with a new hemodialysis catheter between December 2016 and March 2020 were included. HD-CRBSI events reported were compared with the adjudicated outcomes using the end point definition and adjudication processes of the REDUcing the burden of Catheter ComplicaTIOns: a National approach trial. The concordance level was estimated using Gwet agreement coefficient (AC1) adjusted for service-level effects and implementation tranches (Australia only), with the primary outcome being the concordance of confirmed HD-CRBSI. Results: A total of 744 hemodialysis catheter-related infectious events were reported among 7258 patients, 12,630 catheters, and 1.3 million catheter-exposure days. The majority were confirmed HD-CRBSI, with 77.9% agreement and substantial concordance (AC1=0.77; 95% confidence interval [CI], 0.73 to 0.81). Exit site infections have the highest concordance (AC1=0.85; 95% CI, 0.78 to 0.91); the greatest discordance was in events classified as other (AC1=0.33; 95% CI, 0.16 to 0.49). The concordance of all hemodialysis catheter infectious events remained substantial (AC1=0.80; 95% CI, 0.76 to 0.83) even after adjusting for the intervention tranches in Australia and overall service-level clustering. Conclusions: There was a substantial level of concordance in overall and service-level reporting of confirmed HD-CRBSI. A standardized end point definition of HD-CRBSI resulted in comparable hemodialysis catheter infection rates in Australian and New Zealand kidney services. Consistent end point definition could enable reliable benchmarking outside clinical trials without the need for independent clinical adjudication.